Serum levels and genotype distribution of α1-antitrypsin in the general population

Ilaria Ferrarotti, Gian Andri Thun, Michele Zorzetto, Stefania Ottaviani, Medea Imboden, Christian Schindler, Arnold Von Eckardstein, Lucia Rohrer, Thierry Rochat, Erich W. Russi, Nicole M. Probst-Hensch, Maurizio Luisetti

Research output: Contribution to journalArticle

Abstract

Rationale: α1-Antitrypsin (AAT) deficiency is one of the commonest rare respiratory disorders worldwide. Diagnosis, assessment of risk for developing chronic obstructive pulmonary disease (COPD), and management of replacement therapy require the availability of precise and updated ranges for protein serum levels. Objective: This paper aims to provide ranges of serum AAT according to the main genotype classes in the general population. Methods: The authors correlated mean AAT serum levels with the main SERPINA1 variants (M1Ala/M1Val (rs6647), M3 (rs1303), M2/M4 (rs709932), S (rs17580) and Z (rs28929474)) in 6057 individuals enrolled in the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort. Results: The following ranges (5th-95th percentile) of AAT were found in the serum (g/litre): 1.050-1.640 for PI*MM, 0.880-1.369 for PI*MS, 0.730-1.060 for PI*SS, 0.660-0.997 for PI*MZ and 0.490-0.660 for PI*SZ. There was very little overlap in AAT serum levels between genotype classes generally not believed to confer an enhanced health risk (MM and MS) and those associated with an intermediate AAT deficiency and a potentially mildly enhanced health risk (SS, MZ). Conclusion: This work resulted in three important findings: technically updated and narrower serum ranges for AAT according to PI genotype; a suggestion for a population-based 'protective threshold' of AAT serum level, used in decision-making for replacement therapy; and more precise ranges framing the intermediate AAT deficiency area, a potential target for future primary prevention.

Original languageEnglish
Pages (from-to)669-674
Number of pages6
JournalThorax
Volume67
Issue number8
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Genotype
Serum
Population
Air Pollution
Health
Primary Prevention
Disease Management
Chronic Obstructive Pulmonary Disease
Lung Diseases
Blood Proteins
Decision Making
Cohort Studies
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Serum levels and genotype distribution of α1-antitrypsin in the general population. / Ferrarotti, Ilaria; Thun, Gian Andri; Zorzetto, Michele; Ottaviani, Stefania; Imboden, Medea; Schindler, Christian; Von Eckardstein, Arnold; Rohrer, Lucia; Rochat, Thierry; Russi, Erich W.; Probst-Hensch, Nicole M.; Luisetti, Maurizio.

In: Thorax, Vol. 67, No. 8, 08.2012, p. 669-674.

Research output: Contribution to journalArticle

Ferrarotti, I, Thun, GA, Zorzetto, M, Ottaviani, S, Imboden, M, Schindler, C, Von Eckardstein, A, Rohrer, L, Rochat, T, Russi, EW, Probst-Hensch, NM & Luisetti, M 2012, 'Serum levels and genotype distribution of α1-antitrypsin in the general population', Thorax, vol. 67, no. 8, pp. 669-674. https://doi.org/10.1136/thoraxjnl-2011-201321
Ferrarotti, Ilaria ; Thun, Gian Andri ; Zorzetto, Michele ; Ottaviani, Stefania ; Imboden, Medea ; Schindler, Christian ; Von Eckardstein, Arnold ; Rohrer, Lucia ; Rochat, Thierry ; Russi, Erich W. ; Probst-Hensch, Nicole M. ; Luisetti, Maurizio. / Serum levels and genotype distribution of α1-antitrypsin in the general population. In: Thorax. 2012 ; Vol. 67, No. 8. pp. 669-674.
@article{3fef90e6d64c448d863b64e1f4ad7da1,
title = "Serum levels and genotype distribution of α1-antitrypsin in the general population",
abstract = "Rationale: α1-Antitrypsin (AAT) deficiency is one of the commonest rare respiratory disorders worldwide. Diagnosis, assessment of risk for developing chronic obstructive pulmonary disease (COPD), and management of replacement therapy require the availability of precise and updated ranges for protein serum levels. Objective: This paper aims to provide ranges of serum AAT according to the main genotype classes in the general population. Methods: The authors correlated mean AAT serum levels with the main SERPINA1 variants (M1Ala/M1Val (rs6647), M3 (rs1303), M2/M4 (rs709932), S (rs17580) and Z (rs28929474)) in 6057 individuals enrolled in the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort. Results: The following ranges (5th-95th percentile) of AAT were found in the serum (g/litre): 1.050-1.640 for PI*MM, 0.880-1.369 for PI*MS, 0.730-1.060 for PI*SS, 0.660-0.997 for PI*MZ and 0.490-0.660 for PI*SZ. There was very little overlap in AAT serum levels between genotype classes generally not believed to confer an enhanced health risk (MM and MS) and those associated with an intermediate AAT deficiency and a potentially mildly enhanced health risk (SS, MZ). Conclusion: This work resulted in three important findings: technically updated and narrower serum ranges for AAT according to PI genotype; a suggestion for a population-based 'protective threshold' of AAT serum level, used in decision-making for replacement therapy; and more precise ranges framing the intermediate AAT deficiency area, a potential target for future primary prevention.",
author = "Ilaria Ferrarotti and Thun, {Gian Andri} and Michele Zorzetto and Stefania Ottaviani and Medea Imboden and Christian Schindler and {Von Eckardstein}, Arnold and Lucia Rohrer and Thierry Rochat and Russi, {Erich W.} and Probst-Hensch, {Nicole M.} and Maurizio Luisetti",
year = "2012",
month = "8",
doi = "10.1136/thoraxjnl-2011-201321",
language = "English",
volume = "67",
pages = "669--674",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Serum levels and genotype distribution of α1-antitrypsin in the general population

AU - Ferrarotti, Ilaria

AU - Thun, Gian Andri

AU - Zorzetto, Michele

AU - Ottaviani, Stefania

AU - Imboden, Medea

AU - Schindler, Christian

AU - Von Eckardstein, Arnold

AU - Rohrer, Lucia

AU - Rochat, Thierry

AU - Russi, Erich W.

AU - Probst-Hensch, Nicole M.

AU - Luisetti, Maurizio

PY - 2012/8

Y1 - 2012/8

N2 - Rationale: α1-Antitrypsin (AAT) deficiency is one of the commonest rare respiratory disorders worldwide. Diagnosis, assessment of risk for developing chronic obstructive pulmonary disease (COPD), and management of replacement therapy require the availability of precise and updated ranges for protein serum levels. Objective: This paper aims to provide ranges of serum AAT according to the main genotype classes in the general population. Methods: The authors correlated mean AAT serum levels with the main SERPINA1 variants (M1Ala/M1Val (rs6647), M3 (rs1303), M2/M4 (rs709932), S (rs17580) and Z (rs28929474)) in 6057 individuals enrolled in the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort. Results: The following ranges (5th-95th percentile) of AAT were found in the serum (g/litre): 1.050-1.640 for PI*MM, 0.880-1.369 for PI*MS, 0.730-1.060 for PI*SS, 0.660-0.997 for PI*MZ and 0.490-0.660 for PI*SZ. There was very little overlap in AAT serum levels between genotype classes generally not believed to confer an enhanced health risk (MM and MS) and those associated with an intermediate AAT deficiency and a potentially mildly enhanced health risk (SS, MZ). Conclusion: This work resulted in three important findings: technically updated and narrower serum ranges for AAT according to PI genotype; a suggestion for a population-based 'protective threshold' of AAT serum level, used in decision-making for replacement therapy; and more precise ranges framing the intermediate AAT deficiency area, a potential target for future primary prevention.

AB - Rationale: α1-Antitrypsin (AAT) deficiency is one of the commonest rare respiratory disorders worldwide. Diagnosis, assessment of risk for developing chronic obstructive pulmonary disease (COPD), and management of replacement therapy require the availability of precise and updated ranges for protein serum levels. Objective: This paper aims to provide ranges of serum AAT according to the main genotype classes in the general population. Methods: The authors correlated mean AAT serum levels with the main SERPINA1 variants (M1Ala/M1Val (rs6647), M3 (rs1303), M2/M4 (rs709932), S (rs17580) and Z (rs28929474)) in 6057 individuals enrolled in the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort. Results: The following ranges (5th-95th percentile) of AAT were found in the serum (g/litre): 1.050-1.640 for PI*MM, 0.880-1.369 for PI*MS, 0.730-1.060 for PI*SS, 0.660-0.997 for PI*MZ and 0.490-0.660 for PI*SZ. There was very little overlap in AAT serum levels between genotype classes generally not believed to confer an enhanced health risk (MM and MS) and those associated with an intermediate AAT deficiency and a potentially mildly enhanced health risk (SS, MZ). Conclusion: This work resulted in three important findings: technically updated and narrower serum ranges for AAT according to PI genotype; a suggestion for a population-based 'protective threshold' of AAT serum level, used in decision-making for replacement therapy; and more precise ranges framing the intermediate AAT deficiency area, a potential target for future primary prevention.

UR - http://www.scopus.com/inward/record.url?scp=84864018755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864018755&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2011-201321

DO - 10.1136/thoraxjnl-2011-201321

M3 - Article

C2 - 22426792

AN - SCOPUS:84864018755

VL - 67

SP - 669

EP - 674

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 8

ER -